**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Previously Presented) A 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine compound represented by a formula (I) or a pharmaceutically acceptable salt thereof



( I )

wherein the symbols have the following meanings:

$R^1$: amino which may be substituted, -OH or –O-lower alkyl,

$R^2$: $CF_3$ or halogen,

$R^3$: H or halogen,

a, b: each represents single bond or double bond, wherein one is single bond and the other is double bond,

-X-:

(1) –CH=CH-, -CH=N-, -N=CH-, -N=N- or –S- when a is single bond and b is double bond,

(2) –N- when a is double bond and b is single bond,

Y:

(1) CH or N when a is single bond and b is double bond,

(2) S when a is double bond and b is single bond,

-A-: -O-, -S-, -NH- or –N(lower alkyl), and

B: lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl or aryl, each of which may be substituted.

2. (Previously Presented) The compound or pharmaceutically acceptable salt thereof described in claim 1, wherein $R^1$ is a group represented by a formula (II), a formula (III), -OH or –O-lower alkyl



(II)



(III)

wherein the symbols have the following meanings:

$Z^1$: single bond, lower alkylene or –lower alkylene-C(=O)-,

$R^{11}$: lower alkyl which may be substituted with a group selected from the group consisting of -OH, -O-lower alkyl, $-CO_2H$, $-CO_2$-lower alkyl and carbamoyl which may be substituted with one or two lower alkyls, or –H,

$R^{12}$:

(1) when $Z^1$ represents single bond or lower alkylene,

-H, -OH, -O-lower alkyl, $-CO_2H$, $-CO_2$-lower alkyl, carbamoyl which may be substituted with one or two lower alkyls, aryl which may be substituted, cycloalkyl which may be substituted, aromatic hetero ring which may be substituted or non-aromatic hetero ring which may be substituted,

(2) when $Z^1$ represents –lower alkylene-C(=O)-,

a group represented by the formula (III) or a formula (IV)



(III)



(IV)

wherein the symbols have the following meanings:

$Z^2$: single bond or lower alkylene, and

$R^{15}$: -H, -OH, -O-lower alkyl, $-CO_2H$, $-CO_2$-lower alkyl, carbamoyl which may be substituted with one or two lower alkyls, aryl which may be substituted, cycloalkyl which may be substituted, aromatic hetero ring which may be substituted or non-aromatic hetero ring which may be substituted,

$R^{13}$, $R^{14}$: together with the adjacent nitrogen atom, non-aromatic cyclic amino group.

3. (Previously Presented) The compound or pharmaceutically acceptable salt thereof described in claim 2, wherein $R^1$ is a group represented by the formula (II) or formula (III).

4. (Previously Presented) The compound or pharmaceutically acceptable salt thereof described in claim 3, wherein a is single bond, b is double bond, -X- is –CH=CH-, and –Y- is –CH-.

5. (Previously Presented) The compound or pharmaceutically acceptable salt thereof described in claim 4, wherein $R^1$ is a group represented by the formula (II).

6. (Previously Presented) The compound or pharmaceutically acceptable salt thereof described in claim 5, wherein –A- is –O-.

7. (Previously Presented) The compound or pharmaceutically acceptable salt thereof described in claim 6, wherein –B is lower alkyl which may be substituted.

8. (Previously Presented) The compound or pharmaceutically acceptable salt thereof described in claim 7, wherein $R^2$ is trifluoromethyl, and $R^3$ is –H or -F.

9. (Currently Amended) The compound described in claim 1, which is

(2Z)-N-(2-amino-2-oxoethyl)-2-{4,4,7-trifluoro-1-[4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide,

(2Z)-N-(2-hydroxyethyl)-2-{4,4,7-trifluoro-1-[4-{[(2S)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide,

(2Z)-N-(2-hydroxyethyl)-2-{4,4,7-trifluoro-1-[4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide,

(2Z)-2-{4,4-difluoro-1-[4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2S)-2,3-dihydroxypropyl]acetamide,

3-[((2Z)-2-{4,4,7-trifluoro-1-[4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetyl)amino]propanamide, ~~or~~

(2Z)-N-[(2R)-2,3-dihydroxypropyl]-2-{4,4,7-trifluoro-1-[4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide,

(2Z)-N-(2-amino-2-oxoethyl)-2-{4,4,7-trifluoro-1-[4-{[(2S)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide,

(2Z)-2-{1-[4-(2,2-difluoropropoxy)-2-(trifluoromethyl)benzoyl]-4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-(2-hydroxyethyl)acetamide,

(2Z)-2-{4,4-difluoro-1-[4-{[(2S)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-(2-hydroxyethyl)acetamide,

(2Z)-2-{4,4-difluoro-1-[4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-(2-hydroxyethyl)acetamide,

(2Z)-2-{1-[4-(2,2-difluoropropoxy)-2-(trifluoromethyl)benzoyl]-4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-(2-hydroxyethyl)acetamide,

(2Z)-N-[(2R)-2,3-dihydroxypropyl]-2-{4,4,7-trifluoro-1-[4-propoxy-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide,

(2Z)-2-{4,4-difluoro-1-[4-{[(2S)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2S)-2,3-dihydroxypropyl]acetamide,

(2Z)-2-{4,4-difluoro-1-[4-{[(2R)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2R)-2,3-dihydroxypropyl]acetamide,

3-[((2Z)-2-{4,4,7-trifluoro-1-[4-{[(2S)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetyl)amino]propanamide,

(2Z)-N-[(2R)-2,3-dihydroxypropyl]-2-{4,4,7-trifluoro-1-[4-{[(2S)-2-fluoropropyl]oxy}-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetamide,

3-[((2Z)-2-{1-[4-(2,2-difluoropropoxy)-2-(trifluoromethyl)benzoyl]-4,4,7-trifluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}acetyl)amino]propanamide,

(2Z)-2-{4,4-difluoro-1-[4-propoxy-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2R)-2,3-dihydroxypropyl]acetamide, or

(2Z)-2-{4,4-difluoro-1-[4-propoxy-2-(trifluoromethyl)benzoyl]-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene}-N-[(2S)-2,3-dihydroxypropyl]acetamide,

or a pharmaceutically acceptable salt thereof.

10. (Previously Presented) A pharmaceutical composition which comprises the compound or pharmaceutically acceptable salt thereof described in claim 1 as an active ingredient.

11.-12. (Cancelled)